Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. - Wikidata - wikimedia - TriplyDB

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.

http://www.wikidata.org/entity/Q37094986

about

Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations: a report of seven cases and literature review.Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions.Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.

P2860

Q33779741-9103DAE1-84A2-46E7-ACC6-A96FE93F94CF Q38710426-B0CB6F68-5FEF-41AD-90B2-6B6C7FD846DD Q41523237-E40C497B-862F-4008-B578-0CDB7CFC05DD Q47261717-85EFC86C-2F6D-4A74-A16F-F932F62D35A2 Q47838653-0E4878A0-B9B2-436D-AF3F-C048DC44BBC3 Q52430499-AB55B988-4BF6-424E-9327-A6160999E0B1 Q54979668-9FE41940-5FAF-4D55-8844-A76AA6035E2B

P2860

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.

http://www.wikidata.org/entity/Q37094986

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical efficacy of first-gen ...... boring EGFR exon 20 mutations.

@en

Clinical efficacy of first-gen ...... boring EGFR exon 20 mutations.

@nl

type

label

Clinical efficacy of first-gen ...... boring EGFR exon 20 mutations.

@en

Clinical efficacy of first-gen ...... boring EGFR exon 20 mutations.

@nl

prefLabel

Clinical efficacy of first-gen ...... boring EGFR exon 20 mutations.

@en

Clinical efficacy of first-gen ...... boring EGFR exon 20 mutations.

@nl

P1433

Q37094986-DB146427-27D8-426A-94BC-7EDB3E27C41F

P1476

Q37094986-37C9A628-298C-483D-A4D7-DB90E27784BF

P2093

Q37094986-1AC0AB10-BC1A-44E0-9CEF-26284ABBAF09

Q37094986-62FDE100-6BED-4C41-B9D1-D2540DA0A9E6

Q37094986-EAA1C217-6085-43AE-8996-92000BBC3E57

P2860

Q37094986-06ABA4AC-042E-4B0F-B529-FDE5D8BBA35D

Q37094986-0938DDFF-3078-463F-A125-FB748A8CC61A

Q37094986-1147261C-E37D-46D7-A818-B89512C923DD

Q37094986-197CDAD3-0642-4FCD-A222-7F94E035C6A5

Q37094986-1E6DFD9B-9175-4406-85F4-DE3ED37E7A52

Q37094986-1F6F3CD2-0A65-4E5E-9229-9CC3789CA403

Q37094986-3B3C95A1-DE32-4FA2-B85A-B2AED9D5F810

Q37094986-3C065D1D-45D6-4C11-A598-F51552F6799B

Q37094986-3D948265-5EC1-4894-9B3C-E6137202F6B4

Q37094986-776DC6D3-23FB-402A-AC7F-BE1F754EB858

P304

Q37094986-23CBB390-28F7-453B-852A-F6F1D17DDC5E

P31

Q37094986-1795F595-0C33-4648-9A4E-348606696407

P356

Q37094986-A2991392-4C71-4C88-AF36-A7EA062331DC

P407

Q37094986-569BB1B5-A302-422B-8A77-E5EC59700B34

P478

Q37094986-E59BE9F8-6E7C-4C65-9535-90E17F9DB17C

P577

Q37094986-29CA8888-EA14-4A5F-A1EA-19A67AA56B80

P698

Q37094986-BBFE2966-7BBB-49BE-B4F7-83DE43EE53C7

P932

Q37094986-5547A3C1-B778-44E8-92A7-489EE068F3A7

P356

P1433

OncoTargets and Therapy

P1476

Clinical efficacy of first-gen ...... boring EGFR exon 20 mutations.

@en

P2093

Dan Chen

http://www.w3.org/2001/XMLSchema#string

Guoping Cheng

http://www.w3.org/2001/XMLSchema#string

Zhengbo Song

http://www.w3.org/2001/XMLSchema#string

P2860

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

The incidences and mortalities of major cancers in China, 2010.

P304

4181-4186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S108242

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27468240

http://www.w3.org/2001/XMLSchema#string

P932

4944908

http://www.w3.org/2001/XMLSchema#string